<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article is a review and evaluation of the world literature on the systemic use of <z:chebi fb="0" ids="8430">procaine</z:chebi> in the treatment of the aging process and the common <z:hpo ids='HP_0011010'>chronic</z:hpo> diseases of later life </plain></SENT>
<SENT sid="1" pm="."><plain>Included are data from 285 articles and books, describing treatment in more than 100,000 patients in the past 25 years </plain></SENT>
<SENT sid="2" pm="."><plain>Except for a possible antidepressant effect, there is no convincing evidence that <z:chebi fb="0" ids="8430">procaine</z:chebi> (or Gerovital, of which <z:chebi fb="0" ids="8430">procaine</z:chebi> is the major component) has any value in the treatment of disease in older patients </plain></SENT>
<SENT sid="3" pm="."><plain>If <z:chebi fb="0" ids="8430">procaine</z:chebi> has an antidepressant effect, there is some likelihood that this accounts for the reports of decreased complaints referable to the musculoskeletal, cardiovascular, <z:chebi fb="32" ids="24621">endocrine</z:chebi> sexual, gastrointestinal and respiratory systems </plain></SENT>
</text></document>